According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), Mira Pharma (stock code: MIRA) announced that its candidate drug Ketamir-2 did not observe clinically significant dissociative or psychosis-inducing side effects in Phase I clinical trials.

According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), Mira Pharma (stock code: MIRA) announced that its candidate drug Ketamir-2 did not observe clinically significant dissociative or psychosis-inducing side effects in Phase I clinical trials.

老虎证券2026/03/03 21:42

Show original

The results of this trial mark a significant advancement in the safety profile of Ketamir-2, paving the way for its subsequent clinical development. The company emphasized that this discovery is expected to drive further exploration of the drug in therapeutic applications.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), Mira Pharma (stock code: MIRA) announced that its candidate drug Ketamir-2 did not observe clinically significant dissociative or psychosis-inducing side effects in Phase I clinical trials.

You may also like

Trending news

Crypto prices